Efficacy and safety of the proprotein convertase subtilisin / kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study - Kereiakes, D J; Robinson, J G; Cannon, C P (Amer Heart J, 2015)
et al.